[go: up one dir, main page]

NO20062198L - Bradykinin B1 reseptorantagonister - Google Patents

Bradykinin B1 reseptorantagonister

Info

Publication number
NO20062198L
NO20062198L NO20062198A NO20062198A NO20062198L NO 20062198 L NO20062198 L NO 20062198L NO 20062198 A NO20062198 A NO 20062198A NO 20062198 A NO20062198 A NO 20062198A NO 20062198 L NO20062198 L NO 20062198L
Authority
NO
Norway
Prior art keywords
bradykinin
receptor antagonists
peptides
conjugated peptides
present
Prior art date
Application number
NO20062198A
Other languages
English (en)
Inventor
Thomas Storz
Yue Li
Amico Derin C D
Gordon Ng
Colin V Gegg
Jr Benny C Askew
Yuelie Lu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20062198L publication Critical patent/NO20062198L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)

Abstract

Foreliggende oppfinnelse vedrører visse biologisk aktive peptider og konjugerte peptider som kan anvendes terapeutisk eller profylaktisk mot sykdommer eller tilstander forbundet med BI som det forårsakende middel. I en foretrukket utførelessform av oppfinnelsen blir biologisk aktive PEG-konjugerte peptider tilveiebrakt. I et aspekt av foreliggende oppfinnelse er farmasøytisk aktive PEG-konjugerte peptider ifølge oppfinnelsen anvendelige for å behandle inflammasjon eller smerte.
NO20062198A 2003-10-22 2006-05-15 Bradykinin B1 reseptorantagonister NO20062198L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51391303P 2003-10-22 2003-10-22
US53892904P 2004-01-24 2004-01-24
US10/972,236 US7605120B2 (en) 2003-10-22 2004-10-21 Antagonists of the brandykinin B1 receptor
PCT/US2004/034976 WO2005042027A2 (en) 2003-10-22 2004-10-22 Antagonists of the bradykinin b1 receptor

Publications (1)

Publication Number Publication Date
NO20062198L true NO20062198L (no) 2006-07-18

Family

ID=34990807

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062198A NO20062198L (no) 2003-10-22 2006-05-15 Bradykinin B1 reseptorantagonister

Country Status (15)

Country Link
US (4) US7605120B2 (no)
EP (1) EP1677830B1 (no)
JP (1) JP4896728B2 (no)
KR (2) KR100860654B1 (no)
AU (1) AU2004285467A1 (no)
BR (1) BRPI0415755A (no)
CA (1) CA2545499A1 (no)
EA (1) EA009294B1 (no)
EC (1) ECSP066575A (no)
ES (1) ES2395546T3 (no)
IL (1) IL175084A0 (no)
MA (1) MA28160A1 (no)
NO (1) NO20062198L (no)
SG (1) SG149872A1 (no)
WO (1) WO2005042027A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1750683E (pt) * 2004-04-23 2013-01-25 Amgen Inc Formulações de libertação sustida
WO2006116565A2 (en) * 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
CA2800389A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008153967A1 (en) * 2007-06-08 2008-12-18 Contec Therapeutics, Inc. Bk1 antagonist conjugates
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009120565A2 (en) 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
JP2012521360A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
WO2010110887A1 (en) * 2009-03-24 2010-09-30 Robert Shorr Fatty acids
CA2805572A1 (en) * 2010-07-16 2012-01-19 Martin Hegen Modified single domain antigen binding molecules and uses thereof
EP2725034B1 (en) 2010-09-22 2019-04-03 Amgen Inc. Carrier immunoglobulins with no specificity for human tissues and uses thereof
DE102011118029A1 (de) * 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
CA3151034A1 (en) * 2021-03-03 2022-09-03 Kashiv Biosciences, Llc Bioassay method for compounds useful to treat pain
WO2025147774A1 (en) * 2024-01-10 2025-07-17 Alpha-9 Oncology Inc. Compositions targeting bradykinin receptor b1 for medical imaging and treatment of cancer and other disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435642A1 (de) 1974-07-24 1976-02-05 Hoffmann La Roche Traegermaterial
US4693993A (en) 1985-06-13 1987-09-15 Stewart John M Bradykinin antagonist peptides
US4801613A (en) 1985-06-13 1989-01-31 Nova Technology Limited Partnership Bradykinin antagonist peptides
US4923963A (en) 1987-09-02 1990-05-08 Nova Technology Limited Partnership Bradykinin antagonist peptides
EP0318162A3 (en) 1987-11-25 1990-11-07 Texaco Development Corporation Novel bismaleimide derivatives
US5648333A (en) 1988-11-24 1997-07-15 Hoechst Aktiengesellschaft Peptides having bradykinin antagonist action
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5863899A (en) 1991-04-01 1999-01-26 Cortech, Inc. Bradykinin antagonists
US5416191A (en) 1991-04-01 1995-05-16 Cortech, Inc. Bradykinin antagonists
EP0618810B1 (en) 1991-04-19 2001-07-04 Scios Nova Inc. Bradykinin antagonist peptides
US6407207B1 (en) 1992-03-30 2002-06-18 Merck & Co., Inc. Cloned and expressed human bradykinin BK-2 receptor
US5521158A (en) 1992-10-08 1996-05-28 Scios Nova Inc. Pseudopeptide bradykinin receptor antagonists
US5541286A (en) 1992-10-08 1996-07-30 Scios Nova Inc. Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JPH09511500A (ja) 1994-03-09 1997-11-18 コーテック，インコーポレイティド Ｎ−置換化グリシンを含むブラジキニン拮抗薬ペプチド
US5648336A (en) 1994-11-18 1997-07-15 University Of Colorado Bradykinin antagonist peptides containing indane-substituted amino acids
US5849863A (en) 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
US5834431A (en) * 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
WO1998007746A1 (en) 1996-08-19 1998-02-26 Universite De Sherbrooke B1-bradykinin receptor antagonists and use thereof
JP3274076B2 (ja) 1996-12-16 2002-04-15 セイコーインスツルメンツ株式会社 ペプチド断片を得る方法
US5935932A (en) 1997-06-13 1999-08-10 University Technology Corporation Bradykinin antagonists containing pentafluorophenylalanine
US6388054B1 (en) 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
AU2001238595A1 (en) * 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
ATE549354T1 (de) * 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
KR20050051686A (ko) * 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도
WO2004080412A2 (en) * 2003-03-07 2004-09-23 The University Of Toledo Paclitaxel hybrid derivatives

Also Published As

Publication number Publication date
US8288351B2 (en) 2012-10-16
ECSP066575A (es) 2006-10-17
US20090137483A1 (en) 2009-05-28
CA2545499A1 (en) 2005-05-12
WO2005042027A3 (en) 2006-02-09
EA009294B1 (ru) 2007-12-28
EP1677830B1 (en) 2012-10-17
AU2004285467A1 (en) 2005-05-12
KR100860654B1 (ko) 2008-09-26
ES2395546T3 (es) 2013-02-13
KR20080015054A (ko) 2008-02-15
WO2005042027A2 (en) 2005-05-12
JP4896728B2 (ja) 2012-03-14
IL175084A0 (en) 2006-08-20
SG149872A1 (en) 2009-02-27
EA200600817A1 (ru) 2006-12-29
BRPI0415755A (pt) 2006-12-19
EP1677830A2 (en) 2006-07-12
KR20060105757A (ko) 2006-10-11
US8278280B2 (en) 2012-10-02
US20050215470A1 (en) 2005-09-29
AU2004285467A2 (en) 2005-05-12
US20090137452A1 (en) 2009-05-28
JP2007526240A (ja) 2007-09-13
US20090048149A1 (en) 2009-02-19
US7605120B2 (en) 2009-10-20
MA28160A1 (fr) 2006-09-01

Similar Documents

Publication Publication Date Title
NO20062198L (no) Bradykinin B1 reseptorantagonister
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
PT2336184E (pt) Administração de agentes para o tratamento da inflamação
CL2003002353A1 (es) Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
TW200605870A (en) Topical methadone compositions and methods for using the same
AU2003243719A1 (en) Topical administration of pharmacologically active bases in the treatment of warts
WO2002076439A3 (en) Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
NO20053111L (no) Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2006096173A8 (en) Pharmaceutical compositions and methods for peptide treatment
DE602005002653D1 (de) Stabilisierte zusammensetzungen mit einem therapeutischen wirkstoff; zitronensäure oder einer konjugierten base und chlordioxid
EP2510941A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
ZA200704285B (en) Reverse micelles based on phytosterols and acyglycerols and therapeutic uses thereof
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
PT1492773E (pt) Compostos de 4-(heterociclilo)-benzenossulfoximinapara o tratamento da inflamação
ATE423114T1 (de) Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten
PT1150704E (pt) Melagatran para o tratamento da inflamacao
WO2005123192A3 (en) Improving pain treatment with strontium combinations
WO2005082070A3 (en) Compositions and methods for the systemic treatment of arthritis
ATE477805T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
WO2006117404A3 (de) Topische verwendung von radikalfangenden substanzen zur antipyretischen behandlung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application